TX-SNOW-SOFTWARE
14.12.2022 17:01:37 CET | Business Wire | Press release
Snow Software, the global leader in technology intelligence, today released its latest survey which uncovers how IT decision makers’ priorities have shifted over the past 12 months and their top areas of focus as they head into 2023. The Snow Software 2023 IT Priorities Report polled 800 IT leaders from the United States, United Kingdom, Germany and Australia, and highlights that innovation remains a top priority for organizations (94%). However, reducing costs and managing security risks are competing for leaders’ attention and resources amid continuous market volatility.
Due to economic uncertainty and geopolitical disruptions upending the technology landscape, IT teams have shrinking or stagnant budgets and resources, yet the same goals and KPIs to meet. With increased pressure to foster innovation, boost productivity and remain competitive with fewer resources, IT leaders are struggling to identify where to put their time, energy and spend, resulting in continual strategy pivots.
Responding to Uncertainty in the Market
The report shows that economic uncertainty over the past year has forced nearly all IT leaders to rethink their strategy (80%), with 70% noting immense budget impacts.
When navigating resource reductions and market disruption, IT leaders rely on data and their previous experience to guide decision making. This is particularly true when taking risks and pursuing innovation initiatives, as data is needed to reinforce and rationalize prioritization when resources are limited. While IT leaders feel there is an abundance of data available to them, 89% say IT must invest in tools and technologies to extract value from their data and turn it into actionable intelligence.
Shifting Role of the CIO
Given technology deployments and data insights are often used to provide context through ongoing market volatility, many IT leaders are feeling the weight of their organization’s investments on their shoulders.
The role of the CIO has evolved significantly over the last three years, earning them decision making power not just around technology spend, but across the full scope and impact of the company’s bottom line. With this level of decision making power comes even greater accountability, and the same IT leaders who championed the shift to remote work are also at risk of becoming the scapegoats when businesses are not equipped for unprecedented events. CIOs and other IT leaders are living in an age of adaptation: new technologies, new market dynamics, new value drivers, and they are expected to successfully guide their organizations through a new reality of continual, crisis-fueled change.
“The reality is that IT isn’t going to get a break from the uncertainties impacting businesses anytime soon,” said Alastair Pooley, Chief Information Officer at Snow. “The IT leaders that push through the challenges with confidence all have one thing in common: the ability to access data and leverage it strategically. CIOs should not overlook the power of intelligence on their technology, given it empowers IT teams with data-driven insights to shift their focus from tactical response to strategic initiatives. This shift helps drive continued innovation through extended periods of uncertainty.”
Key Findings Include:
- Competing priorities are stalling IT teams’ ability to forward innovation. While innovation remains a priority for IT leaders, it is stalled as businesses wrestle with reducing cost (33%), managing security risks (28%) and advancing digital transformation (26%) – which leaves IT teams conflicted on where to focus their day-to-day efforts versus long-term strategic views.
- The role of the CIO is continuing to evolve. Over the past 18 months, 78% of respondents reported that the role has evolved immensely over this time. Further, 90% of CIOs say they are trusted advisors to the business, as opposed to a one-stop shop for technology. As expected, the evolution of their role has come with increased responsibilities, such as having more accountability for the financial impact of their IT investments (89%), as well as an expectation to innovate faster and demonstrate ROI (85%). CIOs are tasked with juggling many timely problems and priorities, all while ensuring they are meeting their individual goals and expectations.
- IT leaders are both thriving and drowning in data. The report reveals that 89% of IT leaders have access to actionable data to apply to decision making. However, 60% say they are overwhelmed by data, and 89% say IT must invest in tools and technologies to extract value from their data and turn it into actionable intelligence. A data-led approach is the most reliable way to navigate uncertainty, as it provides leaders with an evidence-based roadmap, as well as arming them with the confidence to make data-driven decisions, even in a rapidly changing environment. CIOs and IT leaders with threadbare teams and budgets will be challenged to do it all and need to rely on easily accessible data to drive optimal business decisions. In 2023, approaches like Technology Intelligence – or the ability to understand and manage all technology – will be the catalyst to continued success.
For more information about the latest version of the Snow annual report, please visit: https://www.snowsoftware.com/go/it-priorities/
About Snow Software
Snow Software is changing the way organizations understand and manage their technology consumption. Our technology intelligence platform provides comprehensive visibility and contextual insight across software, SaaS, hardware and cloud. With Snow, IT leaders can effectively optimize resources, enhance performance and enable operational agility in a hybrid world. To learn more, visit www.snowsoftware.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221214005320/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
